- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06937944
Effektivitet og sikkerhed ved rekombinant botulinumtoksin Type A (Eveotox) til injektion til behandling af moderat til svære glabellære linjer
En klinisk fase 3 -undersøgelse for at evaluere effektiviteten og sikkerheden ved rekombinant botulinumtoksin Type A til injektion (Eveotox) sammenlignet med en enkelt behandling af Botox og placebo, og gentagen behandling af Eveotox i moderat til svære glabellare linjer
This is a Phase 3 clinical study to evaluate the efficacy, safety, and immunogenicity of single/repeated injections of Eveotox in the treatment of moderate to severe glabellar lines. The study consists of Study Part 1 (randomized double-blind controlled study) and Part 2 (open-label study). Part I is a multicenter, randomized, double-blind, single-injection, active-controlled and placebo-controlled study to evaluate the efficacy, safety, and immunogenicity of Eveotox in the treatment of moderate to severe glabellar lines; Part 2 is an open-label study to evaluate the efficacy, safety, and immunogenicity of repeated injections of Eveotox in the treatment of moderate to severe glabellar lines.
Studieoversigt
Status
Betingelser
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 3
Kontakter og lokationer
Studiekontakt
- Navn: Danhua Lin
- Telefonnummer: 15811460241
- E-mail: danhua.lin@jhm-biopharma.com
Undersøgelse Kontakt Backup
- Navn: Lei Wang
- E-mail: lei.wang@jhm-biopharma.com
Studiesteder
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kina
- Rekruttering
- Peking Union Medical College Hospital
-
Beijing, Beijing Municipality, Kina
- Rekruttering
- Peking University First Hospital
-
Beijing, Beijing Municipality, Kina
- Rekruttering
- Peking University Third Hospital
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, Kina
- Rekruttering
- The First Affiliated Hospital of Chongqing Medical University
-
-
Guangdong
-
Guangzhou, Guangdong, Kina
- Rekruttering
- The First Affiliated Hospital of Jinan University
-
Guangzhou, Guangdong, Kina
- Rekruttering
- The Third Affiliated Hospital of Sun Yat-sen University
-
-
Hebei
-
Shijiazhuang, Hebei, Kina
- Rekruttering
- The First Hospital of Hebei Medical University
-
-
Hunan
-
Changsha, Hunan, Kina
- Rekruttering
- The Third Xiangya Hospital of Central South University
-
-
Jiangsu
-
Xuzhou, Jiangsu, Kina
- Rekruttering
- The Affiliated Hospital of Xuzhou Medical University
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Kina
- Rekruttering
- Huashan Hospital, Fudan University
-
-
Shanxi
-
Xianyang, Shanxi, Kina
- Rekruttering
- Xianyang Hospital of Yan'an University
-
-
Sichuan
-
Chengdu, Sichuan, Kina
- Rekruttering
- West China Hospital, Sichuan University
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Kina
- Rekruttering
- Tianjin Medical University General Hospital
-
-
Zhejiang
-
Hangzhou, Zhejiang, Kina
- Rekruttering
- Zhejiang Provincial People's Hospital
-
Hangzhou, Zhejiang, Kina
- Rekruttering
- Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Male or female subjects who are between 18 to 65 years of age
- Moderate or severe glabellar lines during maximum frown based on the Investigator Global Assessment Frown Wrinkle Severity scale
- Moderate or severe glabellar lines during maximum frown based on the Patient Frown Wrinkle Severity scale
- Willing and able to follow all trial procedures, attend all scheduled visits, and successfully complete the trial
Exclusion Criteria:
- Subjects who have a history of oversensitivity to the Botulinum Toxin A type or other components of the study drug
- Subjects who have implanted any permanent materials in the glabellar area or received semi-permanent fillers within the first 2 years of screening
- Subjects with active skin infections at the injection site or systemic skin disease, which the investigator judges can affect the evaluation of efficacy or safety
- Subjects who have a history of injecting drugs similar to the study drug within 6 months prior to selection or are foreseen to use during the study period
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Tredobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Eveotox
Eveotox, 20 Units, divided into five injections into the glabellar area. Administered in double-blind fashion at cycle 1 followed by up to 3 open-label cycles. |
Rcombinant botulinum toxin type A for injection(Eveotox) |
|
Aktiv komparator: OnabotulinumtoxinA (Botox )
Botox,20 Units, will be administered in double-blind fashion during treatment cycle 1 only, followed by up to 3 of Eveotox(20 Units). |
OnabotulinumtoxinA (Botox) |
|
Placebo komparator: Placebo
Placebo, will be administered in double-blind fashion during treatment cycle 1 only, followed by up to 3 of Eveotox(20 Units) |
Placebo |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Primary Outcome Measure
Tidsramme: Within 4 weeks
|
Facial Wrinkle Scale (FWS) score of 0 or 1 and an improvement of ≥ 2 points in FWS score (at maximum frown) at week 4 visit relative to baseline, based on both the investigators´ and the subjects´ in-clinic assessments. |
Within 4 weeks
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Secondary Outcome Measure
Tidsramme: Within 52 weeks
|
Incidence of serious adverse events and drug-related adverse events during the study. |
Within 52 weeks
|
Samarbejdspartnere og efterforskere
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- JHM03-CT301
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .